AR075531A1 - Derivados de piperazin-ciclopropil benzamidas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central, tales como alzheimer y esquizofrenia, entre otros - Google Patents

Derivados de piperazin-ciclopropil benzamidas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central, tales como alzheimer y esquizofrenia, entre otros

Info

Publication number
AR075531A1
AR075531A1 ARP100100499A ARP100100499A AR075531A1 AR 075531 A1 AR075531 A1 AR 075531A1 AR P100100499 A ARP100100499 A AR P100100499A AR P100100499 A ARP100100499 A AR P100100499A AR 075531 A1 AR075531 A1 AR 075531A1
Authority
AR
Argentina
Prior art keywords
alkyl
formula
nr11r12
benzamidas
ciclopropil
Prior art date
Application number
ARP100100499A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42631518&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR075531(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR075531A1 publication Critical patent/AR075531A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/108Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Reivindicacion 1: Un compuesto de formula 1, o enantiomeros o diastereomeros de este, o sales farmacéuticamente aceptables de formula (1), o enantiomeros o diastereomeros de estas, o mezcIas de estos: donde: R1 es arilo, heteroarilo, -alquilC1-6-alcoxiC1-3, -aIquilC1-6-hidroxi, -alquilC1-6-C(=O)-NR11R12, -S(=O)2NR11R12, heterociclo, ciano, haloaquilo, -C(=O)NR11R12, alcoxi o halogeno; R2 es aIquiloC1-6 o cicloalquiloC3-6; R3, R4, R5, R6, R7, R5, R9, y R10 se seleccionan cada uno independientemente de H y alquiIoC1-3; y R11 y R12 se seleccionan cada uno independientemente entre H, -alquilC1-6, -alquilC1-3- alcoxiC1-3, un heterocicloalquilo de 5 miembros que contiene al menos un heteroátomo seleccionado entre O y N, un heterocicloalquilo de 6 miembros que contiene al menos un heteroátomo seleccionado entre O y N, -(alquilC1-3)-(heteroarilo de 5 miembros que contiene al menos un heteroátomo seleccionado entre O y N), -(alquiIC1-3)-(heteroarilo de 6 miembros que contiene al menos un heteroátomo seIeccionado entre O y N), haloalquilo, o R11, R12 y el N al cual están unidos se agrupan para formar un heterocicloalquilo seleccionado entre pirrolidinilo, morfolinilo, pipendinilo y piperazinilo, donde dicho heterocicloalquilo está opcionalmente sustituido por al menos un sustituyente seleccionado entre -aIquiloC1-3 y -alquiloC1-6-alcoxiC1-3; y siempre y cuando: i) al menos uno de R3, R4, R5, R6, R7, R8, R9 y R10 es un alquiloC1-3; ii) Ia formula 1 no es (2) cuando R1 es un grupo -C(=O)NR11R12 unida en la posicion meta al fenilo, R2 es isopropilo y R11 y R12 son H; y iii) la formula 1 no está en configuracion cis en el ciclopropano.
ARP100100499A 2009-02-20 2010-02-19 Derivados de piperazin-ciclopropil benzamidas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central, tales como alzheimer y esquizofrenia, entre otros AR075531A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15406709P 2009-02-20 2009-02-20

Publications (1)

Publication Number Publication Date
AR075531A1 true AR075531A1 (es) 2011-04-06

Family

ID=42631518

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100499A AR075531A1 (es) 2009-02-20 2010-02-19 Derivados de piperazin-ciclopropil benzamidas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central, tales como alzheimer y esquizofrenia, entre otros

Country Status (39)

Country Link
US (3) US8993577B2 (es)
EP (1) EP2398780B1 (es)
JP (2) JP5666480B2 (es)
KR (1) KR20110126628A (es)
CN (2) CN104398516A (es)
AR (1) AR075531A1 (es)
AU (1) AU2010216454B2 (es)
BR (1) BRPI1007817A2 (es)
CA (1) CA2752796A1 (es)
CO (1) CO6400219A2 (es)
CR (1) CR20110447A (es)
CU (2) CU20110161A7 (es)
DK (1) DK2398780T3 (es)
DO (1) DOP2011000270A (es)
EA (2) EA020093B1 (es)
EC (1) ECSP11011280A (es)
ES (1) ES2416464T3 (es)
HK (2) HK1164863A1 (es)
HN (1) HN2011002261A (es)
HR (1) HRP20130579T1 (es)
IL (1) IL214277A (es)
ME (1) ME01619B (es)
MX (1) MX2011008280A (es)
NI (1) NI201100160A (es)
NZ (1) NZ595248A (es)
PE (2) PE20151281A1 (es)
PL (1) PL2398780T3 (es)
PT (1) PT2398780E (es)
RS (1) RS52851B (es)
SA (1) SA110310136B1 (es)
SG (1) SG173449A1 (es)
SI (1) SI2398780T1 (es)
SM (1) SMT201300077B (es)
SV (1) SV2011004008A (es)
TW (1) TW201039825A (es)
UA (1) UA108841C2 (es)
UY (1) UY32460A (es)
WO (1) WO2010096011A1 (es)
ZA (1) ZA201106821B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9108948B2 (en) * 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
CN103382174A (zh) * 2006-06-23 2013-11-06 雅培制药有限公司 作为组胺h3受体调节物的环丙胺衍生物
ES2442926T3 (es) * 2007-08-22 2014-02-14 Astrazeneca Ab Derivados de ciclopropilamida `978
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
SG183231A1 (en) * 2010-02-18 2012-09-27 Astrazeneca Ab Solid forms comprising a cyclopropyl amide derivative
MX336333B (es) * 2010-02-18 2016-01-15 Astrazeneca Ab Nueva forma cristalina de un derivado de ciclopropilbenzamida.
WO2012037258A1 (en) 2010-09-16 2012-03-22 Abbott Laboratories Processes for preparing 1,2-substituted cyclopropyl derivatives
ES2901197T3 (es) 2016-03-22 2022-03-21 Merck Sharp & Dohme Moduladores alostéricos de los receptores nicotínicos de la acetilcolina
WO2022059779A1 (ja) 2020-09-18 2022-03-24 大日本住友製薬株式会社 アミン誘導体

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637271A (es) 1963-04-04 1900-01-01
NL128365C (es) 1963-11-05
US3449427A (en) 1965-06-03 1969-06-10 Smithkline Corp Aminocyclopropane derivatives of 5h-dibenzo(a,d)cycloheptenes
US3697506A (en) 1970-08-07 1972-10-10 Pfizer Crystalline alkali metal salts of {60 -carboxybenzylpenicillin and process therefor
US3686335A (en) 1970-12-21 1972-08-22 Smith Kline French Lab 5-vinyl-5h-di benzo(a,d)cycloheptenes
US4432987A (en) 1982-04-23 1984-02-21 Pfizer Inc. Crystalline benzenesulfonate salts of sultamicillin
US4547505A (en) 1983-03-25 1985-10-15 Degussa Aktiengesellschaft N-Phenyl-N-'-cycloalkylalkanoylpiperazine useful as analgetics and process for its production
CS244821B2 (en) 1983-06-16 1986-08-14 Boehringer Ingelheim Ltd Production method of new substituted phenylalkyl(piperazinyl or homopiperazinyle)-prpylureas or thioureas
DE3418167A1 (de) 1984-05-16 1985-11-21 Bayer Ag, 5090 Leverkusen Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen heteroaryloxyacetamiden
DE3600288A1 (de) 1986-01-08 1987-07-16 Bayer Ag Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen sulfonylharnstoff-derivaten
DE3618004A1 (de) 1986-05-28 1987-12-03 Bayer Ag Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen sulfonyliso(thio)-harnstoff-derivaten
WO1991009594A1 (en) 1989-12-28 1991-07-11 Virginia Commonwealth University Sigma receptor ligands and the use thereof
CA2033390A1 (en) 1989-12-29 1991-06-30 Susumu Nakagawa 2-(2-cyclopropylpyrrolidin-4-ylthio) carbapenem derivatives
JPH06505502A (ja) 1991-08-22 1994-06-23 モンサント・カンパニー 毒性緩和除草剤ピラゾリルスルホニル尿素
DE4131139A1 (de) 1991-09-19 1993-03-25 Bayer Ag Verfahren zur herstellung von 1-fluor-cyclopropan-1-carbonsaeure
CA2155322C (en) 1993-03-12 2000-02-29 Michael J. Dunn Crystalline ceftiofur free acid
CN1088062C (zh) 1994-11-23 2002-07-24 纽罗根公司 某些4-氨基甲基-2-取代的咪唑衍生物2-氨基甲基-4-取代的咪唑衍生物新的一族多巴胺受体亚型特异性配体
US5604253A (en) 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5859246A (en) 1997-01-30 1999-01-12 Neurogen Corporation 1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands
AU6179998A (en) 1997-02-24 1998-09-09 Zymogenetics Inc. Calcitonin mimetics
US6160134A (en) 1997-12-24 2000-12-12 Bristol-Myers Squibb Co. Process for preparing chiral cyclopropane carboxylic acids and acyl guanidines
EA200000768A1 (ru) 1998-01-27 2001-06-25 Эвентис Фармасьютикалз Продактс Инк. ЗАМЕЩЕННЫЕ ОКСОАЗАГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ ФАКТОРА Ха
US6268367B1 (en) 1998-02-23 2001-07-31 Zymogenetics, Inc. Piperazine derivatives for treating bone deficit conditions
AU4531499A (en) 1998-06-26 2000-01-17 Chugai Seiyaku Kabushiki Kaisha Fine powder of l-alpha-aminoadipic acid derivative, oral solid preparations containing the same, and method for treatment of bulk powders
US6284761B1 (en) 1999-01-08 2001-09-04 Neurogen Corporation 1-phenyl-4-(1-[2-aryl]cyclopropyl)methylpiperazines: dopamine receptor ligands
AU771199B2 (en) 1999-01-08 2004-03-18 Neurogen Corporation 1-phenyl-4-(1-(2-aryl)cyclopropyl) methylpiperazines: dopamine receptor ligands
WO2000076993A1 (fr) 1999-06-16 2000-12-21 Takeda Chemical Industries, Ltd. Derives de benzazepine, procede de preparation de ces derives et utilisation
AU7715300A (en) 1999-09-27 2001-04-30 Merck & Co., Inc. Method of preventing osteoporosis
JP2003519698A (ja) 2000-01-07 2003-06-24 トランスフォーム ファーマスーティカルズ,インコーポレイテッド 多様な固体形態のハイスループットでの形成、同定および分析
US6521619B2 (en) 2000-06-29 2003-02-18 Icos Corporation Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents
AU2001268724B2 (en) 2000-06-29 2005-06-16 Abbott Laboratories Aryl phenycyclopropyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
NZ523526A (en) 2000-07-20 2004-10-29 Neurogen Corp Diaryl piperazines as capsaicin receptor ligands
WO2002051781A1 (fr) 2000-12-25 2002-07-04 Ajinomoto Co., Inc. Procede permettant de preparer un compose d'halohydrine optiquement actif
UA75392C2 (en) 2001-02-23 2006-04-17 Merck & Co Inc N-substituted non-aryl heterocyclic antagonists nmda/nr2b
AU2002344951A1 (en) 2001-07-02 2003-01-21 Boehringer Ingelheim International Gmbh Substituted piperazine and diazepanes as histamine h3 receptor agonists
US7262185B2 (en) 2001-08-08 2007-08-28 Takeda Chemical Industries Ltd. Benzazepine derivative, process for producing the same, and use
CA2457642C (en) 2001-09-26 2009-01-06 Merck & Co., Inc. Crystalline forms of ertapenem sodium
WO2003037271A2 (en) 2001-10-30 2003-05-08 Millennium Pharmaceuticals,Inc. Compounds, pharmaceutical compositions and methods of use therefor
US6861432B2 (en) 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
IL164044A0 (en) 2002-03-22 2005-12-18 Lg Life Sciences Ltd New crystalline forms of (2S)-N-5-Äamino(inino)methylÜ-2-thienylmethyl-1-(2R)-2-Ä(carboxsymethyl)aminoÜ-3,3-diphenylpropanoyl-2-pyrrolidinecarboxamide-nh2o
WO2003103666A2 (en) 2002-06-07 2003-12-18 Altana Pharma Ag Novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones
US20040209858A1 (en) 2002-10-22 2004-10-21 Bennani Youssef L. Cycloalkylamides and their therapeutic applications
US20040077618A1 (en) 2002-10-22 2004-04-22 Bennani Youssef L. Cycloalkylamides and their therapeutic applications
JPWO2004046110A1 (ja) 2002-11-15 2006-03-16 アステラス製薬株式会社 メラニン凝集ホルモン受容体拮抗剤
US7569579B2 (en) 2002-12-13 2009-08-04 Smithkline Beecham Corporation Cyclopropyl compounds as ccr5 antagonists
PL1615909T3 (pl) 2003-04-23 2009-01-30 Glaxo Group Ltd Pochodne piperazyny i ich zastosowanie w leczeniu chorób neurologicznych i psychicznych
EP1620108B1 (en) 2003-05-01 2012-06-06 Bristol-Myers Squibb Company Pyrazole-amine compounds useful as kinase inhibitors
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
CN1901971A (zh) 2003-12-15 2007-01-24 日本烟草产业株式会社 环丙烷化合物及其药物应用
ATE537830T1 (de) 2004-07-06 2012-01-15 Xenon Pharmaceuticals Inc Nicotinamid derivate und ihre verwendung als therapeutika
AR050865A1 (es) 2004-09-09 2006-11-29 Sanofi Aventis Derivados de 2- morfolino-4-pirimidona
BRPI0515851A (pt) 2004-09-29 2008-08-12 Mitsubishi Pharma Corp composto de pirimidona
PL1802307T3 (pl) 2004-10-15 2008-07-31 Glaxo Group Ltd Pochodne pirolidyny jako ligandy receptorów histaminowych
EP1833800A1 (en) 2004-12-27 2007-09-19 AstraZeneca AB Pyrazolone compounds as metabotropic glutamate receptor agonists for the treatment of neurological and psychiatric disorders
EP1844052A1 (en) 2005-01-26 2007-10-17 Pharmacia & Upjohn Company LLC Thieno[2,3-d]pyrimidine compounds as inhibitors of adp-mediated platelets aggregation
ATE517867T1 (de) 2005-02-15 2011-08-15 Glaxo Group Ltd Verbindungen, die den glutamatrezeptor verstärken und anwendungen davon in der medizin
ES2433290T3 (es) 2005-02-17 2013-12-10 Astellas Pharma Inc. Derivados de piperazina para el tratamiento de la incontinencia urinaria y el dolor
WO2006100591A1 (en) 2005-03-25 2006-09-28 Pharmacia & Upjohn Company Llc 4-piperazinnylthieno [2,3-d] pyrimidine compounds as platelet aggregation inhibitors
WO2006103555A1 (en) 2005-03-28 2006-10-05 Pharmacia & Upjohn Company Llc 4-piperazinothieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors
CA2602227A1 (en) 2005-03-28 2006-10-05 Michael Dalton Ennis 4-piperazinylthieno [2,3-d] pyrimidine compounds as platelet aggregation inhibitors
JP2008534570A (ja) 2005-03-28 2008-08-28 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 血小板凝集阻害薬としての4−ピペラジニルチエノ[2,3−d]ピリミジン化合物
MX2008000745A (es) 2005-07-15 2008-03-14 Schering Corp Derivados de quinazolina utiles en el tratamiento del cancer.
TW200740779A (en) 2005-07-22 2007-11-01 Mitsubishi Pharma Corp Intermediate compound for synthesizing pharmaceutical agent and production method thereof
WO2007016496A2 (en) 2005-08-02 2007-02-08 Neurogen Corporation Dipiperazinyl ketones and related analogues
BRPI0622428A2 (pt) * 2005-09-16 2021-05-11 Janssen Pharmaceutica N.V. ciclopropila aminas como moduladores do receptor h3 de histamina
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
UA93892C2 (ru) 2005-10-31 2011-03-25 Янссен Фармацевтика H.B. Способ получения производных циклопропиламида (варианты
TW200740803A (en) 2005-12-21 2007-11-01 Vertex Pharma Heterocyclic derivatives as modulators of ion channels
WO2007076140A2 (en) 2005-12-23 2007-07-05 University Of Cincinnati Treatment methods employing histamine h3 receptor antagonists, including betahistine
BRPI0707916A2 (pt) 2006-01-13 2011-05-17 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem e uso destes compostos
CN101384581B (zh) 2006-02-17 2013-09-18 弗·哈夫曼-拉罗切有限公司 作为5ht2/d3调节剂的苯甲酰基-哌啶衍生物
MX2008011133A (es) 2006-03-01 2008-12-18 Cementech Pty Ltd Matriz para elementos de albañileria y metodo de fabricacion de la misma.
JP2009132621A (ja) 2006-03-13 2009-06-18 Ajinomoto Co Inc シクロプロピルアミド化合物の製造方法
MX2008012064A (es) 2006-03-23 2008-12-17 Amgen Inc Compuestos de amida 1-fenilsulfonil-diaza-heterociclica y sus usos como moduladores de hidroxiesteroide deshidrogenadas.
EP2039689A4 (en) 2006-05-26 2011-12-28 Kaneka Corp PROCESS FOR PREPARING OPTICALLY ACTIVE 3-AMINO-2-HYDROXYPROPIONIC ACID CYCLOPROPYLAMID DERIVATIVES AND SALTS THEREOF
CN103382174A (zh) * 2006-06-23 2013-11-06 雅培制药有限公司 作为组胺h3受体调节物的环丙胺衍生物
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
EP2044027A2 (en) 2006-07-03 2009-04-08 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Fused bicyclic compounds interacting with the histamine h4 receptor
US20090247499A1 (en) 2006-08-21 2009-10-01 Fletcher Joan M Sulfonylated piperazines as cannabinoid-1 receptor modulators
TW200828371A (en) 2006-09-21 2008-07-01 Matsushita Electric Ind Co Ltd Chip-type filter
DE102006056526A1 (de) 2006-11-30 2008-06-05 Archimica Gmbh Verfahren zur stereoselektiven Synthese von chiralen Epoxiden durch ADH-Reduktion von alpha-Abgangsgruppen-substituierten Ketonen und Cyclisierung
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
WO2008147864A2 (en) * 2007-05-22 2008-12-04 Xenon Pharmaceuticals Inc. Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions
WO2008150364A1 (en) 2007-05-23 2008-12-11 Merck & Co., Inc. Cyclopropyl pyrrolidine orexin receptor antagonists
CA2688585A1 (en) * 2007-06-11 2008-12-18 F. Hoffmann-La Roche Ag Cyclohexyl derivatives
ES2442926T3 (es) * 2007-08-22 2014-02-14 Astrazeneca Ab Derivados de ciclopropilamida `978
MX2010003155A (es) 2007-10-04 2010-04-01 Hoffmann La Roche Derivados de ciclopropil aril amida y uso de los mismos.
CL2009000004A1 (es) 2008-01-15 2010-02-19 Lilly Co Eli Forma cristalina de r-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida; composicion farmaceutica que comprende a dicha forma cristalina; y uso para el tratamiento de diabetes o hiperglicemia.
DE102008049371A1 (de) 2008-03-06 2009-09-10 Mühlbauer Ag Einrichtung mit einem RFID-Transponder in einem elektrisch leitfähigen Gegenstand und Herstellungsverfahren hierfür
WO2009135842A1 (en) 2008-05-08 2009-11-12 Evotec Neurosciences Gmbh Azetidines and cyclobutanes as histamine h3 receptor antagonists
JP2012503595A (ja) 2008-07-28 2012-02-09 シダンスク ユニバーシティ 代謝病の治療用の化合物
CN101462980B (zh) 2009-01-05 2013-01-09 扬州天辰精细化工有限公司 2,6—二氟苯甲酰胺的工业化生产方法
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
MX336333B (es) 2010-02-18 2016-01-15 Astrazeneca Ab Nueva forma cristalina de un derivado de ciclopropilbenzamida.
SG183231A1 (en) 2010-02-18 2012-09-27 Astrazeneca Ab Solid forms comprising a cyclopropyl amide derivative

Also Published As

Publication number Publication date
SG173449A1 (en) 2011-09-29
CA2752796A1 (en) 2010-08-26
CU20110161A7 (es) 2012-02-15
DOP2011000270A (es) 2012-08-31
IL214277A (en) 2015-08-31
EA201190140A1 (ru) 2012-03-30
US8993577B2 (en) 2015-03-31
SV2011004008A (es) 2012-01-06
TW201039825A (en) 2010-11-16
CU20140013A7 (es) 2014-04-24
PL2398780T3 (pl) 2013-08-30
ME01619B (me) 2014-09-20
AU2010216454A1 (en) 2011-08-25
EP2398780A4 (en) 2012-09-19
CN102405213A (zh) 2012-04-04
UY32460A (es) 2010-09-30
SA110310136B1 (ar) 2014-01-14
US20100216812A1 (en) 2010-08-26
US20150164888A1 (en) 2015-06-18
BRPI1007817A2 (pt) 2017-05-30
NI201100160A (es) 2012-03-15
SMT201300077B (it) 2013-09-06
HN2011002261A (es) 2014-07-31
ES2416464T3 (es) 2013-08-01
EA020093B1 (ru) 2014-08-29
JP5666480B2 (ja) 2015-02-12
HRP20130579T1 (en) 2013-07-31
JP2012518634A (ja) 2012-08-16
EP2398780B1 (en) 2013-04-17
AU2010216454B2 (en) 2013-05-02
US20150164889A1 (en) 2015-06-18
PT2398780E (pt) 2013-06-25
HK1208348A1 (en) 2016-03-04
IL214277A0 (en) 2011-09-27
CO6400219A2 (es) 2012-03-15
NZ595248A (en) 2014-01-31
KR20110126628A (ko) 2011-11-23
EA201490268A1 (ru) 2015-07-30
CR20110447A (es) 2011-09-19
SI2398780T1 (sl) 2013-08-30
ECSP11011280A (es) 2011-09-30
PE20151281A1 (es) 2015-10-04
RS52851B (en) 2013-12-31
ZA201106821B (en) 2012-06-26
HK1164863A1 (en) 2012-09-28
PE20120063A1 (es) 2012-03-04
DK2398780T3 (da) 2013-07-01
MX2011008280A (es) 2011-08-24
CN102405213B (zh) 2014-11-19
CN104398516A (zh) 2015-03-11
JP2015071634A (ja) 2015-04-16
EP2398780A1 (en) 2011-12-28
UA108841C2 (ru) 2015-06-25
WO2010096011A1 (en) 2010-08-26

Similar Documents

Publication Publication Date Title
AR075531A1 (es) Derivados de piperazin-ciclopropil benzamidas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central, tales como alzheimer y esquizofrenia, entre otros
AR119651A1 (es) Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington
AR055150A1 (es) Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso
AR069480A1 (es) Derivados de 2-amino-pirimidina
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
AR070343A1 (es) Piridinil amidas, un procedimiento para el tratamiento de la esquizofrenia en un mamifero y una composicion farmaceutica
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
AR056979A1 (es) Derivados de dihidrobenzofuranos y usos de los mismos
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
AR079226A1 (es) Espiroindolinona- pirrolidinas, procesos de preparacion y uso de los mismos para el tratamiento y profilaxis del cancer
AR096979A1 (es) Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR089776A1 (es) 5,8-dihidro-6h-pirazolo[3,4-h]quinazolinas como inhibidores de igf-1r/ir
AR082886A1 (es) Compuestos y composiciones farmaceuticas que los contienen
AR084553A1 (es) DERIVADOS IMIDAZOLICOS HETEROCICLICOS INHIBIDORES DE b-SECRETASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA TRATAR ENFERMEDADES NEURODEGENERATIVAS, EN PARTICULAR ALZHEIMER
AR060604A1 (es) Nuevos arilamino n- heteroarilos como inhibidores de mek
AR103742A1 (es) Derivados de trifluorometilpropanamida
AR057703A1 (es) INHIBIDORES MACROCíCLICOS DEL VIRUS DE LA HEPATITIS C. PROCESO DE PREPARACIoN Y COMPOSICIONES FARMACÉUTICAS.
AR044874A1 (es) Derivados de 4- cianopirazol-3 - carboxamida, su preparacion y su aplicacion en terapeutica
AR057380A1 (es) Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
CO6351734A2 (es) Compuestos de amida utiles en terapia
AR075583A1 (es) Derivados de isoxazol/o-piridina con eslabon etilo o etenilo
AR069813A1 (es) Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR087148A1 (es) Imidazopiridazinas
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6

Legal Events

Date Code Title Description
FB Suspension of granting procedure